Two Groups of Philadelphia Chromosome—Positive Childhood Acute Lymphoblastic Leukemia Classified by Pretreatment Multidrug Sensitivity or Resistance in In Vitro Testing Authors
Received: 11 November 2001 Revised: 29 May 2002 Accepted: 31 May 2002 DOI:
Cite this article as: Hongo, T., Okada, S., Inoue, N. et al. Int J Hematol (2002) 76: 251. doi:10.1007/BF02982795 Abstract
The development of effective chemotherapy is imperative for children with Philadelphia chromosome—positive (Ph) acute lymphoblastic leukemia (ALL) because of the poor prognosis of this condition. Initial cellular drug resistance is thought to be an important cause of induction failure and early relapse.We carried out in vitro tests using a methyl-thiazol-tetrazolium assay on bone marrow samples from 274 children with newly diagnosed ALL. Sixteen children (5.8%) had Ph-positive results of cytogenetic analysis. We examined in vitro drug resistance to 14 agents and found that leukemic cells in Ph ALL were significantly more resistant than were cells in non-Ph ALL to melphalan, bleomycin, etoposide, mitoxantrone, L-asparaginase, and vinblastine. With the prednisolone, L-asparaginase, and vincristine (PAV) combination of drugs, 10 of the 16 Ph patients with ALL (62.5%) showed relative resistance (RR) (sensitivity to only 1 or to none of the 3 drugs) at initiation of treatment.These 10 patients experienced significantly poorer event-free survival (EFS) than did the 6 patients with supersensitivity (SS) (defined as sensitivity to all 3 or to 2 of the 3 drugs,
P = .019). Leukemic cells from RR patients were found to be multiresistant to 12 drugs with 2.0- to 58.4-fold RR compared with cells from SS patients. This PAV sensitivity delineates initially sensitive and resistant groups. Of these, the SS subgroup of Ph ALL patients may be curable with chemotherapy and stem cell transplantation. For EFS improvement in the RR group, it may be necessary to use a new chemotherapy approach from initiation. Key words Philadelphia chromosome positive Acute lymphoblastic leukemia Childhood Methyl-thiazol-tetrazolium (MTT) assay Drug resistance Drug sensitivity References
Bloomfield CD, Goldman AI, Alimena G, et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia.
The Groupe Français de Cytogénétique Hématologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Français de Cytogénétique Hématologique.
Fletcher JA, Lynch EA, Kimball VM, Donnelly M, Tantravahi R, Sallan SE. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia.
Crist W, Carroll A, Shuster J, et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome.A Pediatric Oncology Group Study.
Uckun FM, Nachman JB, Sather HN, et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies.
Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
. 1997; 89:2959–2965.
Hongo T, Yamada S, Yajima S, et al. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Int J Hematol.
Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and
drug resistance in 395 children with acute lymphoblastic leukemia: implications for treatment of infants.
Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.
Pui CH. Childhood leukemias.
N Engl J Med.
Roberts WM, Rivera GK, Raimondi SC, et al. Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukemia.
Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome—positive acute lymphoblastic leukemia.
N Engl J Med.
Schrappe M, Arico M, Harbott J, et al. Philadelphia chromosome- positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
Radich JP, Kopecky KJ, Boldt DH, et al. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction.
Voncken JW, Kaartinen V, Pattengale PK, Germeraad WTV, Groffen J, Heisterkamp N.
P210 and P190 cause distinct leukemia in transgenic mice.
Preudhomme C, Henic N, Cazin B, et al. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL).
Kaspers GJL, Kardos G, Pieters R, et al. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.
Kasprzyk A, Harrison CJ, Secker-Walker LM. Investigation of clonal involvement of myeloid cells in Philadelphia chromosome— positive and high hyperdiploid acute lymphoblastic leukemia.
Hongo T, Fujii Y, Igarashi Y. An
chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia.
Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.
Klumper E, Pieters R, Veerman AJP, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia.
Kaspers GJL, Smets LA, Pieters R, van Zantwijk CH, van Wering ER, Veerman ALP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an
Ramakers—van Woerden NL, Pierters R, Hoelzer D, et al. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Med Pediatr Oncol.
Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer.
PubMed CrossRef Copyright information
© The Japanese Society of Hematology 2002